



Press Release

Fixed Phage rebrands to NexaBiome Limited, signifying commitment towards human health sector

UK-based biotechnology company Fixed Phage has changed its name to NexaBiome Limited, pushing forward in its promise to connect science, technology and healthcare to address the global challenge of antimicrobial resistance (AMR), especially in human health. NexaBiome's pioneering work in addressing bacterial issues will also continue in the animal and veterinary health sector, cementing its position as a global end-to-end phage company.

Having recently appointed a new top management team, with Dr Neil Clelland becoming CEO, the company is set to capitalise on its considerable expertise and knowledge in the development of effective and sustainable bacteriophage (phage)-based solutions for hard-to-treat bacterial infections.

The name change is in line with the company's strategy to expand deeper into the human health sector. Its mission is to discover, develop and deliver pioneering treatments to tackle AMR and improve the health and wellbeing of people and animals. This includes the manufacture, discovery and development, and storage and application of phage.

Neil Clelland, NexaBiome CEO, says: "We are really excited with this rebrand, which signifies a refreshed and unwavering commitment towards our extensive and innovative work with phages, and our new focused strategy as an end-to-end phage company in the human and animal health sectors.

"AMR is one of the top 10 global public health threats we face, and phage therapy promises to shape the future of medical science to address these challenges and save lives. At the forefront of this innovation, we are committed to consolidating and building on our work. This rebrand is a milestone that sees us evolving and positioning ourselves better towards the new strategy."

As part of the company's new strategic focus, NexaBiome is embarking on a restructuring exercise to better deliver on its commitment. It has announced two new promotions within the team – making Gordon Smith Principal Scientist and Scott Gourlay Quality Manager.

Chris Bindon, NexaBiome COO, says: "These promotions are an appreciation and recognition of the dedication we see in our people and the critical role they play towards the advancements and development of phage-based solutions for the company."

"We recognise their dedication to personal and company development, and this is a true reflection of the vision the company is committed to. We're very pleased with the team's hard work and these promotions not only support the company's growth, but also our people's progress."

Media contacts:

Pippa Moraitopoulos or Mike Keeler
Garnett Keeler PR
+44 (0)20 8647 4467

pippa.moraitopoulos@garnettkeeler.com
mike.keeler@garnettkeeler.com

Fixed Phage's rebrand involves a name change and is accompanied by a redesign of its logo and website, updating its look and feel, as well as improving the user experience.

ENDS

Notes to Editors:

NexaBiome is an end-to-end biotechnology company focused on addressing the global challenge of antimicrobial resistance and improving human and animal health. Previously known as Fixed Phage, the company is based in Glasgow, Scotland, UK.

With significant expertise in addressing bacterial challenges, NexaBiome's focus is on the discovery, development and provision of effective and sustainable bacteriophage (phage) solutions in the field of human health and animal health.

Bacteriophages are viruses that can target and kill problem bacteria while leaving the beneficial bacteria intact. They are naturally occurring, biodegradable and made from renewable matters.

The company is committed to innovation and harnessing the sustainable power of phage, with its work involving the manufacture, research and development, storage and application of phage, globally.

For more information: www.nexabiome.com | Email: info@nexabiome.com

NXB/006/23